IndiMitecan

SKU: orb1689782

Description

IndiMitecan (LMP776) is a topoisomerase I (Top1) inhibitor developed for anticancer research. It has demonstrated activity in both in vitro cytotoxicity assays and in vivo tumor model studies, supporting its investigation in oncology and pharmacology.

Research Area

Molecular Biology

Key Properties

• CAS Number: 915360-05-3
• MW: 459.45
• Purity: 98.25% (May vary between batches)
• Formula: C₂₅H₂₁N₃O₆
• SMILES: COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCn3ccnc3)c(=O)c2cc1OC
• Target: Topoisomerase
• Solubility: DMSO:7.7 mg/mL (16.76 mM)

Bioactivity

• In Vitro:
  Indimitecan (LMP776) exhibits antiproliferative effects across a variety of human cancer cell lines, demonstrating a mean-graph midpoint (MGM) for growth inhibition at 0.079 ± 0.023 μM, as per the National Cancer Institute's developmental therapeutics assay ("NCI60"). Its potent efficacy is highlighted by its ability to induce DNA cleavage through Top1 inhibition and its role as a substrate for metabolic ketone reductases. In specific cell proliferation assays involving cell lines such as HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, and MCF-7, Indimitecan showed growth inhibition with GI50s ranging from <0.01 to 0.08 μM, underscoring its potent antiproliferative activities across a diverse set of cancer cell lines.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LMP 776, LMP776, LMP-776, IndiMitecan, topoisomerase I

Compound Identifiers

PubChem CID

11519397